A Well-Integrated Sideline. Deal to supply an inhaler device to Daiichi Sankyo marks a big victory for Hovione
C&EN, 8 June, 2009
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
C&EN, 8 June, 2009
A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Hovione’s inhalers offer our business partners access to simple, multipurpose, easy to use, globally competitive alternatives for inhalation delivery devices.
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
HY02, a Proprietary Minocycline Sterile Ointment to Treat a Subset of Anterior Ocular Inflammation
Hovione’s assets represent value for life cycle management strategies, drugs repurposed route of administrations and paragraph IV opportunities in technically difficult generics.